The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ratio of Dietary Calcium to Magnesium on Cardiovascular Risk

NCT04531267

Hypertension Nutritional and Metabolic Diseases Cardiovascular Risk Factor

UNKNOWN NA

Magnesium and Vascular Stiffness

NCT02235805

Metabolic Syndrome Obesity

COMPLETED NA

Study of Macronutrients and Heart Disease Risk

NCT00609271

Obesity Body Composition Blood Pressure +1 more

COMPLETED NA

Dietary Incorporation of Lentils to Improve Metabolic Health

NCT04448067

Waist, Hypertriglyceridemic

COMPLETED NA

Soybean Oil Trial of cArdiovascular Risk

NCT02404207

Cardiovascular Disease Diabetes Metabolic Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.

Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Hypertension Dyslipidemia Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

magnesium L-lactate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly implanted ICD or recent ICD shock (within 6 months)

Exclusion Criteria

* Inability to swallow
* A non-cardiac disease with a survival prognosis of less than 12 months
* Hypermagnesemia
* Creatinine clearance less than 30mL/min
* Lactic acidosis or systemic acidosis syndrome
* Previous intolerance to magnesium L-lactate

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No